Clinical trials: Anhedonia
Stable Schizophrenia
A Randomized, Double-Blind, Placebo Controlled, Two-Period Cross-Over, Proof of Activity Study to Evaluate the Effects of TAK-041 on Motivational Anhedonia as Add-On to Antipsychotics in Participants With Stable Schizophrenia
The purpose of the study is to determine whether motivation/reward deficits observed in schizophrenia are attenuated and whether cognitive impairment associated with schizophrenia is improved by add-on TAK-041 administration to…
- Trial name
- NCT03319953
- Testing
- TAK-041, Second Generation Antipsychotics (SGA)
- Where
- United Kingdom
- Volunteers
- 23 people
- Sponsor
- Neurocrine Biosciences
ANXIETY DISORDERS (or Anxiety and Phobic Neuroses)
Fast-Fail Trials in Mood and Anxiety Spectrum Disorders; Kappa Opioid Receptor Phase 2a
The available treatment for patients with mood and anxiety disorders have significant limitations (Rush, 2007; Denys and de Geus, 2005). There is a need to develop new treatments for people with these disorders.
- Trial name
- FASTMAS_Kor2 (NCT02218736)
- Testing
- CERC-501
- Where
- 6 sites in United States
- Volunteers
- 163 people
- Sponsor
- Duke University
Depression, Bipolar, Depression, Unipolar
Pramipexole to Target "Anhedonic Depression"
The heterogeneity of depression suggests that different neurocircuits and pathophysiological mechanisms are involved. Anhedonia - the inability to experience pleasure from, or the lack of motivation to carry out, usually…
- Conditions
- Depression, Bipolar, Depression, Unipolar, Dysthymia, Anhedonia
- Trial name
- PILOT-PRAXOL (NCT04121091)
- Testing
- Pramipexole Pill
- Where
- Sweden
- Volunteers
- 13 people
- Sponsor
- Region Skane
Depressive Disorder, Anhedonia
Study to Treat Major Depressive Disorder With a New Medication
This project is designed to examine the neuronal KCNQ2/3 potassium (K+) channel subtype as a novel treatment target for mood disorders through the administration of the KCNQ-selective channel opener ezogabine (Potiga…
- Trial name
- NCT03043560
- Testing
- Ezogabine
- Where
- 2 sites in United States
- Volunteers
- 45 people
- Sponsor
- James Murrough
Major Depressive Disorder
BTRX-246040 Administered Once Daily to Patients With Major Depressive Disorder
This study will determine the efficacy, safety, and tolerability of a once-daily (QD) dose of up to 80 mg of BTRX-246040 for 8 weeks in participants with MDD.
- Trial name
- NCT03193398
- Testing
- BTRX-246040 oral capsule(s)
- Where
- 8 sites in United States
- Volunteers
- 104 people
- Sponsor
- BlackThorn Therapeutics, Inc.